Duoning Biotech Showcases Innovative Bioprocessing Solutions at CSGCT 2025 Ahead of Hong Kong IPO Filing

BoothNo.: A107-1

The Transpro series of transient transfection media and its complementary DN Feed supplements, developed by Duoning Bio, are specifically designed for transient transfection and expression in CHO cells. They are compatible with various cell lines, including ExpiCHO-S, CHO-S, and CHO-K1. This animal-component-free, chemically defined (CD) medium supports high-density suspension culture, efficient transfection, and high-level protein expression, facilitating the high-quality production of antibodies and recombinant proteins in life science R&D. The product is easy to prepare, suitable for GMP manufacturing environments, and backed by fully independent intellectual property rights, providing customers with a high-performance, standardized solution for transient transfection culture.

BrPERfect® for Protein

Specialized Transfection Reagent for Protein Production is designed for high-efficiency transient protein expression in 293/CHO cells, requiring only 0.5 mL per liter of cell culture. Based on biodegradable cationic polymer technology, it features low toxicity and no residue. Protein yield significantly surpasses that of competing products, achieving high production levels for both easy-to-express and difficult-to-express molecules. The transfection complexes remain stable at room temperature for 2 hours, offering ease of use and strong batch-to-batch consistency.

BrPERfect® for Virus: High-Efficiency Reagents for Viral Vector Production

Suitable for suspension and adherent cell culture systems in the production of AAV5/6, lentivirus, and other viral vectors. It increases viral titer several-fold, significantly outperforming mainstream competitors. The reagent exhibits low cytotoxicity and leaves no residue. Transfection complexes can be prepared in just 2 minutes and remain stable at room temperature for over 3 hours, making it highly suitable for scale-up and high-throughput operations. With a dosage of only 0.75 mL per liter of cells, it offers an economical and efficient solution.

To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Cell and Gene Therapy (CSGCT) Conference was established.

Leveraging its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Annual Meeting will bring togetherGlobal Excellence in Sciencefamilies, clinical experts, multinational pharmaceutical companies, and overseas investment institutions, bringing the most cutting-edge developments in the global field of cell and gene therapyCutting-edge research advancements, technologies and applications, market access information, high-quality collaboration projects, and overseas investors and investment needsSeeking Collaboration: Building a Platform for In-Depth Exchange and Cooperation Between China’s Cell and Gene Therapy Industry and the Global Supply Chain

The conference closely addressed the industry's hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-forums, coveringLatest Advances in Global Gene Therapy, Immune Cell Therapy, In Vivo CAR-T, Adult Stem Cells and Exosomes, iPSC-Derived Cell Therapies, Small Nucleic Acid Drugs, Gene Editing, Oncolytic Viruses, and Tumor Vaccines, as well as CMC and Testing, AI-Driven Drug Discovery, Registration and Regulation, and Investment, Financing, and BD MatchmakingWaitComprehensive Coverage Across the Entire Industry Chain.

2025 The 2nd China Society for Gene and Cell Therapy (CSGCT) Conference

September 12–13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, scan the QR code to visit the official conference website.